David Greenberg, MD
Ophthalmology · Chicago, ILNPI 1730282187
Payments from drug & device makers
Across 57 payments — averaging $41.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$591
- Glaukos Corporation$407
- Novartis$237
- Bausch & Lomb, A Division Of Bausch Health US, LLC$213
- Eyevance Pharmaceuticals LLC$211
- Alcon$210
- plus $476 from 10 others
What the payments were for
- Consulting fees$50021%
- Food & beverage$1,80677%
- Gifts$392%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 3 | $591 |
| Glaukos Corporation | 4 | $407 |
| Novartis | 12 | $237 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $213 |
| Eyevance Pharmaceuticals LLC | 12 | $211 |
| Alcon | 9 | $210 |
| Medtronic | 1 | $138 |
| Biotissue Holdings Inc. | 1 | $71 |
| Bausch & Lomb Americas Inc. | 3 | $62 |
| Thea Pharma Inc. | 2 | $41 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Ocular Therapeutix, Inc. | 2 | $30 |
| Harrow Eye, LLC | 1 | $29 |
| AbbVie | 1 | $28 |
| Lumibird Medical Inc. | 1 | $20 |
| Aerie Pharmaceuticals, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Whitestar Phacoemulsficiation System$500
- iDose$250
- INVOS$138
- ENVISTA$113
How this compares
$2,345 in reported general payments places this provider in the 60th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 701 | $209,553 |
| XiidraLifitegrast | 155 | $130,269 |
| AlrexLoteprednol Etabonate | 242 | $100,064 |
| CombiganBrimonidine Tartrate/Timolol | 311 | $75,230 |
| RocklatanNetarsudil Mesylat/Latanoprost | 168 | $61,615 |
| RestasisCyclosporine | 70 | $47,878 |
| VyzultaLatanoprostene Bunod | 156 | $45,202 |
| RhopressaNetarsudil Mesylate | 79 | $25,721 |
| IlevroNepafenac | 46 | $17,881 |
| Cyclosporine | 54 | $15,597 |
| CequaCyclosporine | 13 | $10,034 |
| Brimonidine Tartrate | 116 | $9,368 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 39 | $8,976 |
| Restasis MultidoseCyclosporine | 13 | $8,228 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 73 | $7,565 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Restasis Multidose, Alphagan P | $28 | $344,3741,113 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $62 | $175,471311 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCAlrex, Loteprednol Etabonate | $213 | $103,374253 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $20 | $87,335247 claims |
| NovartisIlevro | $237 | $17,88146 claims |
| AlconSimbrinza | $210 | $8,97639 claims |
| Eyevance Pharmaceuticals LLCZerviate | $211 | $2,47711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 773 ophthalmology providers in Illinois.
Other ophthalmology in Chicago
- Seenu HariprasadChicago$2.3M
- Manjot GillChicago$1.4M
- Amani FawziChicago$864K
- Sarah SunshineChicago$664K
- Jennifer LimChicago$636K
- Dilraj GrewalChicago$543K
- Ahmad ArefChicago$355K
- Yannek LeidermanChicago$312K
- Asim FarooqChicago$270K
- Armin AfsharChicago$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.